• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 13, 2022 at 08:32: PM
via Among its dozen FDA approvals for a variety of autoimmune disorders, AbbVie’s Humira has plenty of competition in most of its indications. In the debilitating skin condition hidradenitis suppurativa however, Humira is a solo act—a status it has enjoyed since its FDA nod in 2015.

article source
 




Top Bottom
Back
Quote